Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition

Lederer S, M. H. Dijkstra T, Heskes T (2018)
Frontiers in Pharmacology 9: 31.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Lederer, Simone; M. H. Dijkstra, Tjeerd; Heskes, Tom
Einrichtung
Erscheinungsjahr
2018
Zeitschriftentitel
Frontiers in Pharmacology
Band
9
Art.-Nr.
31
ISSN
1663-9812
eISSN
1663-9812
Page URI
https://pub.uni-bielefeld.de/record/2918898

Zitieren

Lederer S, M. H. Dijkstra T, Heskes T. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Frontiers in Pharmacology. 2018;9: 31.
Lederer, S., M. H. Dijkstra, T., & Heskes, T. (2018). Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Frontiers in Pharmacology, 9, 31. doi:10.3389/fphar.2018.00031
Lederer, Simone, M. H. Dijkstra, Tjeerd, and Heskes, Tom. 2018. “Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition”. Frontiers in Pharmacology 9: 31.
Lederer, S., M. H. Dijkstra, T., and Heskes, T. (2018). Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Frontiers in Pharmacology 9:31.
Lederer, S., M. H. Dijkstra, T., & Heskes, T., 2018. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Frontiers in Pharmacology, 9: 31.
S. Lederer, T. M. H. Dijkstra, and T. Heskes, “Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition”, Frontiers in Pharmacology, vol. 9, 2018, : 31.
Lederer, S., M. H. Dijkstra, T., Heskes, T.: Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Frontiers in Pharmacology. 9, : 31 (2018).
Lederer, Simone, M. H. Dijkstra, Tjeerd, and Heskes, Tom. “Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition”. Frontiers in Pharmacology 9 (2018): 31.

2 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Leveraging Mathematical Modeling to Quantify Pharmacokinetic and Pharmacodynamic Pathways: Equivalent Dose Metric.
McKenna MT, Weis JA, Quaranta V, Yankeelov TE., Front Physiol 10(), 2019
PMID: 31178753
Efficacy of a Combination of N-Palmitoylethanolamide, Beta-Caryophyllene, Carnosic Acid, and Myrrh Extract on Chronic Neuropathic Pain: A Preclinical Study.
Fotio Y, Aboufares El Alaoui A, Borruto AM, Acciarini S, Giordano A, Ciccocioppo R., Front Pharmacol 10(), 2019
PMID: 31316381

29 References

Daten bereitgestellt von Europe PubMed Central.

Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models.
Baeder DY, Yu G, Hoze N, Rolff J, Regoes RR., Philos. Trans. R. Soc. Lond., B, Biol. Sci. 371(1695), 2016
PMID: 27160596
Synergy, additivism and antagonism in immunosuppression. A critical review.
Berenbaum MC., Clin. Exp. Immunol. 28(1), 1977
PMID: 324671
The expected effect of a combination of agents: the general solution.
Berenbaum MC., J. Theor. Biol. 114(3), 1985
PMID: 4021503
What is synergy?
Berenbaum, Pharmacol. Rev. 2(), 1989
The toxicity of poisons applied jointly
Bliss, Ann. Appl. Biol. 26(), 1939
Chemogenomics and orthology-based design of antibiotic combination therapies.
Chandrasekaran S, Cokol-Cakmak M, Sahin N, Yilancioglu K, Kazan H, Collins JJ, Cokol M., Mol. Syst. Biol. 12(5), 2016
PMID: 27222539
Systematic discovery of drug interaction mechanisms.
Chevereau G, Bollenbach T., Mol. Syst. Biol. 11(4), 2015
PMID: 25924924
Systematic exploration of synergistic drug pairs.
Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, Nergiz ME, Costanzo M, Baryshnikova A, Giaever G, Nislow C, Myers CL, Andrews BJ, Boone C, Roth FP., Mol. Syst. Biol. 7(), 2011
PMID: 22068327
Combenefit: an interactive platform for the analysis and visualization of drug combinations.
Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI., Bioinformatics 32(18), 2016
PMID: 27153664
Systems biology and combination therapy in the quest for clinical efficacy.
Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK., Nat. Chem. Biol. 2(9), 2006
PMID: 16921358
Analysis of drug combinations: current methodological landscape.
Foucquier J, Guedj M., Pharmacol Res Perspect 3(3), 2015
PMID: 26171228
Understanding synergy.
Geary N., Am. J. Physiol. Endocrinol. Metab. 304(3), 2012
PMID: 23211518
A unifying concept for assessing toxicological interactions: changes in slope.
Gennings C, Carter WH Jr, Carchman RA, Teuschler LK, Simmons JE, Carney EW., Toxicol. Sci. 88(2), 2005
PMID: 16081521
The Hill equation: a review of its capabilities in pharmacological modelling.
Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P., Fundam Clin Pharmacol 22(6), 2008
PMID: 19049668
The search for synergy: a critical review from a response surface perspective.
Greco WR, Bravo G, Parsons JC., Pharmacol. Rev. 47(2), 1995
PMID: 7568331
An in vivo multiplexed small-molecule screening platform.
Gruner BM, Schulze CJ, Yang D, Ogasawara D, Dix MM, Rogers ZN, Chuang CH, McFarland CD, Chiou SH, Brown JM, Cravatt BF, Bogyo M, Winslow MM., Nat. Methods 13(10), 2016
PMID: 27617390
The possible effects of the aggregation of the molecule of hæmoglobin on its dissociation curves
Hill, J. Physiol. 40(), 1910
Synergistic drug combinations tend to improve therapeutically relevant selectivity.
Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA., Nat. Biotechnol. 27(7), 2009
PMID: 19581876
Chemical combination effects predict connectivity in biological systems.
Lehar J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, Short GF 3rd, Giusti LC, Nolan GP, Magid OA, Lee MS, Borisy AA, Stockwell BR, Keith CT., Mol. Syst. Biol. 3(), 2007
PMID: 17332758
Die quantitativen probleme der pharmakologie
Loewe, Ergebnisse Physiol. 27(), 1928
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.
Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang JK, Michael S, Mierzwa T, Huang W, Walsh MJ, Mott BT, Patel P, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CP, Martin SE, Simeonov A, Ferrer M, Staudt LM, Thomas CJ., Proc. Natl. Acad. Sci. U.S.A. 111(6), 2014
PMID: 24469833

AUTHOR UNKNOWN, 0
Dose-Response Analysis Using R.
Ritz C, Baty F, Streibig JC, Gerhard D., PLoS ONE 10(12), 2015
PMID: 26717316
An isobole-based statistical model and test for synergism/antagonism in binary mixture toxicity experiments
Sørensen, Environ. Ecol. Stat. 14(), 2007
Revisiting the isobole and related quantitative methods for assessing drug synergism.
Tallarida RJ., J. Pharmacol. Exp. Ther. 342(1), 2012
PMID: 22511201
Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.
Yadav B, Wennerberg K, Aittokallio T, Tang J., Comput Struct Biotechnol J 13(), 2015
PMID: 26949479
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 29467650
PubMed | Europe PMC

Suchen in

Google Scholar